Drug Database
VE

verapamil (verapamil, Mylan / verapamil SR, Mylan / verapamil ER)

✓ Approved

Mylan · CACNA1C · 小分子

什么是 verapamil?

verapamil 是一种小分子,由Mylan研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名verapamil, Mylan, verapamil SR, Mylan, verapamil ER
公司Mylan
药物类别小分子
分子靶点CACNA1C
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

verapamil 作用于 1 个分子靶点:

CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

verapamil 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedBBA advances2026-11-17

Inhibition of the OCTN1-mediated acetylcholine transport by quinidine and verapamil.

Pochini Lorena L, Cerbelli Maria Iolanda MI, Galluccio Michele M, Mariem Omar Ben OB et al.

The non-neuronal cholinergic system plays an important role in certain human diseases, such as cancer. The Novel Organic Cation Transporter, OCTN1, mediates the efflux of acetylcholine in the frame of this system, from both normal and tumour cells, providing a localised, non-neuronal source of acetylcholine that plays a crucial role in regulating fundamental cellular processes, including proliferation, differentiation, migration and immune responses. Therefore, inhibiting OCTN1-mediated acetylcholine release with repurposed drugs could represent a novel therapeutic approach. Data previously obtained by computational analysis identified quinidine and verapamil as strong OCTN1 binders. These drugs have been experimentally validated for their effects on acetylcholine transport using proteoliposome assays with both recombinant OCTN1 and OCTN1 extracted from the A549 cell line. This experimental system, based on a single-protein approach, is not affected by interferences, allowing us to describe a mixed-type of inhibition for both drugs, indicating that the binding sites for the substrate and the drugs do not fully overlap. Importantly, a trans-inhibition effect by the two drugs on the acetylcholine release was revealed. The experimental approach used proved advantageous in the highly reliable and rapid identification of the mechanism of inhibition by approved drugs.

PMID 43041283
阅读全文 →
PubMedHeadache2026-11-16

Daridorexant in treatment refractory cluster headache: A retrospective case series.

Querzola Giacomo G, Galli Alberto A, Altavilla Riccardo R, Mauri Michela Anna Maria MAM et al.

Cluster headache (CH) is one of the most excruciating pain conditions known in humans. Most patients experience nocturnal attacks, which further worsen sleep quality and overall quality of life. The management of CH includes acute and preventive treatments, and in some cases, transitional therapy with corticosteroids may be used to achieve pain freedom in a shorter time while giving preventive therapy. We report our preliminary experience with daridorexant, a selective dual orexin receptor antagonist approved for chronic insomnia, as an adjunctive treatment in patients with treatment refractory CH, nocturnal attacks, and bad quality of sleep. Our objective was to describe within-patient changes in nocturnal attack frequency, sleep quality, and headache-related disability before and after add-on daridorexant in refractory CH. In this single-center, retrospective before-after case series, we reviewed clinical data from 10 patients followed at the Headache Center of the San Carlo Borromeo Hospital in Milan (Italy) between June 2023 and December 2024, with a diagnosis of either episodic or chronic CH, who experienced nocturnal attacks, sleep disturbances, and with inadequate response to standard treatments, including verapamil, lithium, or corticosteroids. In these patients, daridorexant was administered as add-on therapy, to treat the chronic insomnia. The frequency and features of CH attacks, sleep quality, headache-related disability, and quality-of-life evaluations were assessed before and after treatment. Treatment with daridorexant was associated with a significant reduction in nocturnal attacks, from 13.1 ± 7.5 to 6.4 ± 7.7 attacks per week (p < 0.050; n = 10/10). Patients also reported improved quality of life, with mean subjective quality-of-life scores increasing from 37% ± 15.6% to 61% ± 20.4% (p = 0.001; n = 10/10). Headache-related impact was reduced, with mean Headache Impact Test 6 scores decreasing from 62.0 ± 7.4 to 48.8 ± 16.2 (p < 0.050; n = 10/10). In addition, no patient reported worsening on the Patient Global Impression of Change scale, and eight of the nine out of 10 available Patient Global Impression of Change ratings indicated improvement. Daridorexant was generally well-tolerated, with adverse events reported in three out of 10 patients (30%), leading to treatment discontinuation in one patient. Daridorexant was significantly associated particularly with a reduction in the number of nocturnal attacks in patients with CH refractory to conventional therapies. These pilot preliminary results suggest a potential role for daridorexant as an adjunctive option for patients with CH, particularly those with a poor response to traditional therapies, nocturnal attacks, and sleep disturbances. Further prospective, controlled studies are warranted to confirm these findings and clarify the mechanisms underlying the observed clinical benefits.

PMID 43036956
阅读全文 →
PubMedClinical practice and cases in emergency medicine2026-11-11

Idiopathic Left Anterior Fascicular Ventricular Tachycardia in the Emergency Department: A Case Report.

Kofman Rochelle R, O'Hare Connor C, Querin Lauren B LB

Idiopathic fascicular ventricular tachycardia is a rare form of ventricular tachycardia that is commonly seen in young, otherwise healthy individuals without structural heart disease. This rhythm can be difficult to distinguish from other forms of tachyarrhythmia, including supraventricular tachycardia, yet acute pharmacologic management of this condition varies significantly from more common forms. We describe a 42-year-old woman with no cardiac history who presented with palpitations and lightheadedness. She was found to be in a hemodynamically stable, wide-complex tachycardia. Given no prior cardiac history, supraventricular tachycardia with aberrancy was initially considered as a leading diagnosis; however, a trial of adenosine and lidocaine was ineffective. Her electrocardiogram revealed a regular wide complex tachycardia at 262 beats per minute with a right bundle branch block morphology and right axis deviation, consistent with a rare left anterior fascicular subtype of ventricular tachycardia. She later underwent successful ablation of the left anterior fascicle with no recurrence of symptoms at follow-up. This report highlights a case of idiopathic fascicular ventricular tachycardia successfully treated with intravenous verapamil and left anterior fascicle ablation, addressing the diagnostic challenges of this arrhythmia. Early recognition by emergency physicians is essential to avoid treatment delays and ensure appropriate definitive management.

PMID 43014405
阅读全文 →
PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-11-06

Prokinetic effect of ferulic acid ethyl ester on gastrointestinal motility in mice: an integrated in silico and in vivo study.

de Carvalho Lima Izabela Borges IB, de Oliveira Marcos Meneses MM, da Costa Douglas Soares DS, Dos Santos Polyanna Negreiros PN et al.

Gastrointestinal paralysis and dysmotility remain clinically relevant conditions associated with delayed intestinal transit, feeding intolerance, prolonged hospitalization, and limited effective pharmacological treatment options. Among these disorders, postoperative ileus (POI) is a common complication after abdominal surgery characterized by transient suppression of coordinated gastrointestinal motility. The present study investigated the effects of ferulic acid ethyl ester (FAEE) on intestinal motility and explored its underlying mechanisms using integrated in silico and in vivo approaches. Gastrointestinal transit was assessed in mice by the charcoal meal test under normal conditions and in an experimental POI model induced by intestinal manipulation. In normal mice, FAEE (50 and 100 mg/kg, p.o.) significantly increased intestinal transit. In POI animals, FAEE (50 mg/kg) significantly attenuated the postoperative delay in intestinal transit. Biochemical analyses showed that FAEE reduced MPO activity, NOx, and MDA levels, while restoring SOD activity and GSH content. Pharmacological studies further indicated that the prokinetic effect of FAEE involves cholinergic and calcium-dependent pathways, as atropine and verapamil significantly attenuated its effects. In contrast, pharmacological blockade of opioid and 5-HT3 receptors did not significantly alter the prokinetic effect of FAEE under the present experimental conditions. Molecular docking predicted favorable binding of FAEE to M3R and CaV1.2. In conclusion, FAEE exerts prokinetic effects and attenuates the development of postoperative dysmotility, with findings suggesting the involvement of cholinergic and calcium-dependent pathways and an association with anti-inflammatory and antioxidant effects.

PMID 42993219
阅读全文 →
PubMedAnnals of translational medicine2026-11-06

First in vivo evaluation of pharmaceutical modulation of porcine ureteral distensibility.

Tano Zachary E ZE, Wu Yi-Xi YX, Gao Bruce M BM, Cumpanas Andrei D AD et al.

Pharmacologic relaxation of ureteral smooth muscle may promote spontaneous stone passage via medical expulsive therapy (MET), reduce renal colic, and facilitate ureteroscopic access to the kidney. We evaluated the effects of six oral smooth muscle relaxants on porcine ureteral distensibility using the novel University of California, Irvine (UCI) force sensor. Thirty-five juvenile female Yorkshire swine contributed 59 evaluable ureters following 7 days of oral treatment with placebo, fasudil, mirabegron, Rowatinex®, silodosin, tadalafil, or verapamil. Distensibility was measured as maximum dilator size passed and ureteral size scale (USS). Generalized estimating equations accounted for bilateral ureters and adjusted for age, baseline bacteriuria, and the corresponding day zero measurement. Primary analyses estimated within-group changes of ureteral distensibility due to fasudil, mirabegron, silodosin, tadalafil, and control, with a Holm correction performed across ten tests. Secondary analyses compared adjusted changes among groups and versus the control group. Untreated controls showed minimal change in ureteral size (+0.2 Fr, P=0.84) or USS (+0.8 points, P=0.73). In the primary, within-group analysis, and before multiplicity correction, fasudil increased ureteral size by 0.78 Fr (P=0.02) and USS by 3.39 points (P<0.001). After Holm correction, only the fasudil-associated USS increase remained significant (adjusted P=0.004). Sensitivity analysis using each group's observed baseline characteristics supported increases with fasudil in size (+0.93 Fr) and USS (+3.48 points), both significant after correction. In the secondary analysis comparing medication groups to control, which was underpowered and had unbalanced baseline characteristics, no medication differed significantly from control after correction. Oral fasudil showed the strongest association with increased porcine ureteral distensibility. These findings warrant an appropriately powered direct comparison between fasudil-treated and untreated control animals. Given the clinical tolerability and safety of fasudil, the findings could also support a clinical evaluation of oral fasudil for MET and ureteral colic in carefully selected patients.

PMID 42991443
阅读全文 →
PubMedPhytomedicine : international journal of phytotherapy and phytopharmacology2026-11-06

Activity of the natural biflavonoid hinokiflavone against multidrug-resistant CEM/ADR5000 leukemia cells and its modes of action via P-glycoprotein modulation.

Lei Xiao X, Taghizadeh Daria Shiva DS, Klauck Sabine M SM, Hai Yuanping Y et al.

Multidrug resistance (MDR), frequently associated with the overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), is a major obstacle to successful leukemia chemotherapy. Natural products represent an important source for anticancer drug discovery. Hinokiflavone, a natural biflavonoid, has demonstrated anticancer potential, but its underlying mechanisms against multidrug-resistant leukemia are largely unknown. We hypothesized that hinokiflavone exhibits preferential activity against P-gp-overexpressing multidrug-resistant leukemia cells through specific mechanisms associated with the multidrug-resistant phenotype. Cytotoxicity was evaluated in parental and drug-resistant cell models, and the contribution of ABCB1/P-gp to the collateral sensitivity of CEM/ADR5000 cells was investigated by siRNA-mediated ABCB1 knockdown. Molecular docking was performed to predict potential interactions with both P-gp and breast cancer resistance protein (BCRP). mRNA-based transcriptomic expression profiling, Western blot analysis, pathway analyses, and siRNA-mediated TXNIP knockdown were used to investigate signaling alterations. Intracellular ROS generation, mitochondrial membrane potential, P-gp-associated drug transport, ATP levels, cell cycle distribution, DNA damage, and apoptosis were further investigated. In addition, a zebrafish xenograft model was used to evaluate preliminary in vivo antitumor activity. Hinokiflavone exhibited collateral sensitivity toward P-gp-overexpressing CEM/ADR5000 leukemia cells, and ABCB1 knockdown markedly reduced this sensitivity. Moreover, hinokiflavone significantly restored doxorubicin sensitivity in multidrug-resistant CEM/ADR5000 cells, reducing the IC₅₀ of doxorubicin by 3.17-fold, comparable to the P-glycoprotein inhibitor verapamil. Molecular docking predicted interactions with both P-gp and BCRP. Transcriptomic and protein analyses revealed alterations in several signaling pathways (activated WNT/β-catenin signaling, increased TXNIP and PTEN expression, and reduced PI3K/AKT/mTOR signaling). TXNIP knockdown attenuated the effects of hinokiflavone on PI3K/AKT/mTOR signaling and reduced the cytotoxic response. Hinokiflavone treatment was also associated with ROS accumulation, mitochondrial membrane depolarization, altered P-gp-associated drug transport, ATP depletion, G2/M-related cell-cycle alterations, DNA damage, and apoptosis. Hinokiflavone additionally exhibited preliminary antitumor activity in an SK-N-DZ zebrafish xenograft model. Hinokiflavone exhibits collateral sensitivity in P-gp-overexpressing CEM/ADR5000 leukemia cells, with ABCB1/P-glycoprotein contributing substantially to this phenotype. Its activity is associated with oxidative stress, energy metabolism, P-gp-associated drug transport, and multiple survival signaling pathways. These findings highlight hinokiflavone's potential for targeting multidrug-resistant leukemia.

PMID 42994334
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多verapamil